Heart Failure

Cardiologists and researchers alike are calling for the early halt of a national heart stem cell trial after Harvard Medical School and Brigham and Women’s Hospital expressed concern earlier this week that some of the work the study is based on might be falsified.

The HeartMate 3 left ventricular assist device (LVAD) has gained FDA approval for advanced heart failure patients ineligible for a transplant, manufacturer Abbott announced Oct. 19.

Right ventricular (RV) strain analysis could be a useful addition to existing methods of risk assessment in patients with acute decompensated heart failure (ADHF), according to recent research that identified RV longitudinal strain from the free wall (RV-fwLS) as an independent predictor of cardiac events in the demographic.

Cleveland Clinic researchers identified amyloid deposits in 10.2 percent of patients undergoing carpal tunnel release surgery, suggesting biopsies of hand tissue could be an early signal of life-threatening cardiac amyloidosis.

Women with a history of cardiotoxicity from previous cancer treatments are around 30 percent more likely to experience clinical congestive heart failure (CHF) before, during or after pregnancy, according to research published ahead of print in the Journal of the American College of Cardiology.

Harvard Medical School scientists have created a wirelessly programmed, miniaturized pacemaker which functions for weeks to months at a time, opening the door to “previously impossible investigations of arrhythmia and heart failure in the mouse.”

Digoxin, a cardiac glycoside popularly sold under the brand name Lanoxin, poses a major threat to the heart health of atrial fibrillation (AF) and heart failure (HF) patients, according to a review published in the American Journal of Cardiology Oct. 4. Even without confounding conditions, the drug can raise an individual’s risk of all-cause mortality.

Women who suffer from peripartum cardiomyopathy (PPCM) will likely be clinically asymptomatic seven years after they give birth, according to research published in the Journal of the American Heart Association Oct. 3—but it’s also likely they’ll develop enduring diastolic dysfunction and reduced exercise capacity in the same window.

The Hospital Readmissions Reduction Program (HRRP) has successfully slashed readmissions for heart failure, acute MI (AMI) and pneumonia without causing mortality increases, according to an analysis of Medicare data published in JAMA Network Open. But the author of an accompanying editorial isn’t convinced the results are so positive.

Heart failure (HF) patients who experience moderate functional mitral regurgitation (FMR) for at least six months after cardiac resynchronization therapy (CRT) are at an increased risk for death, researchers suggest in a study published this week.

Compared to heart failure patients with severe secondary mitral regurgitation who were treated with guideline-directed medical therapy alone, those randomized to a MitraClip procedure plus optimal medical therapy demonstrated relative reductions of 47 percent for heart failure hospitalizations and 38 percent for mortality at two years of follow-up.

Digital games developed for cardiovascular disease self-management improve exercise capacity and energy expenditure among their users, according to a review published Sept. 18 in the Games for Health Journal, but the approach does little to overcome mental hurdles like depression, anxiety and quality of life.